Regulus Therapeutics, Inc.
10614 Science Center Drive
San Diego
California
92121
United States
Tel: 858-202-6300
Fax: 858-202-6363
Website: http://www.regulusrx.com/
Email: careers@regulusrx.com
About Regulus Therapeutics, Inc.
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases.
Regulus is located in La Jolla, California and is led by a seasoned executive team experienced in corporate management, business, science, drug discovery and development. Regulus' scientific advisory board consists of world-class scientists and some of the foremost authorities in the field of microRNA research.
Regulus Seeks Highly Motivated, Innovative and Passionate Team Members
338 articles about Regulus Therapeutics, Inc.
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
3/21/2024
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
-
Regulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
3/12/2024
Regulus Therapeutics Inc. announced positive topline results from the second cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
-
Regulus Therapeutics Announces Oversubscribed $100 Million Private Placement of Equity
3/12/2024
Regulus Therapeutics Inc. announced that it has entered into a definitive securities purchase agreement in connection with a private placement to certain institutional investors and other accredited investors.
-
Regulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
1/2/2024
Regulus Therapeutics Inc. (Nasdaq: RGLS), today announced it has completed enrollment in the third cohort of patients in the Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
-
Regulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
11/22/2023
Regulus Therapeutics Inc today announced that CEO Jay Hagan will be participating in a fireside chat at the 6th Annual Evercore ISI HealthCONx Conference on Wednesday November 29, at 10:25 a.m. ET.
-
Regulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent Updates
11/9/2023
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the third quarter ended September 30, 2023.
-
Regulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
11/2/2023
Regulus Therapeutics Inc. today announced the dosing of the first patient in the third cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.
-
Regulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
10/19/2023
Regulus Therapeutics Inc. today announced, after review of all available safety data, that it will advance to the third cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. Patients in the third cohort will receive 3 mg/kg of RGLS8429 or placebo every other week for three months.
-
Regulus Therapeutics Announces Positive Topline Data from the First Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
9/20/2023
Regulus Therapeutics Inc. today announced positive topline results from the first cohort of patients in its Phase 1b MAD study of RGLS8429 for the treatment of ADPKD.
-
Regulus Therapeutics Announces Completion of Enrollment in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
9/13/2023
Regulus Therapeutics Inc. today announced it has completed enrollment in the second cohort of patients in the ongoing Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.
-
Regulus Therapeutics Announces Participation at Two Healthcare Investment Conferences
9/5/2023
Regulus Therapeutics Inc today announced that the Company will host investor meetings at the Wells Fargo Healthcare Conference, and present and host meetings at the H.C. Wainwright 25th Annual Global Investor Conference.
-
Regulus Therapeutics to Host Virtual Investor Event on September 6, 2023
8/23/2023
Regulus Therapeutics Inc today announced that it will host a virtual investor event on Wednesday, September 6, 2023.
-
Regulus Therapeutics Reports Second Quarter 2023 Financial Results and Recent Updates
8/8/2023
Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today reported financial results and provided a corporate update for the second quarter ended June 30, 2023.
-
Regulus Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
8/2/2023
Regulus Therapeutics Inc today announced that CEO Jay Hagan will be presenting at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023.
-
Regulus Therapeutics to Present at the H.C. Wainwright 2nd Annual Kidney Conference
7/18/2023
Regulus Therapeutics Inc today announced that Dr. Preston Klassen , President and Head of Research & Development of Regulus, will present at the H.C. Wainwright 2nd Annual Kidney Conference on Tuesday, July 25, 2023 at 3:00 p.m. ET.
-
Regulus Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
6/27/2023
Regulus Therapeutics Inc. today announced the dosing of the first patient in the second cohort of the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.
-
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
6/23/2023
Regulus Therapeutics Inc. today announced Preston S. Klassen , M.D., President and Head of Research & Development, has been appointed to the Company's Board of Directors.
-
Regulus Therapeutics Announces Update on Preclinical Studies in Amyotrophic Lateral Sclerosis in Collaboration with Researchers from Harvard's Brigham and Women's Hospital
6/20/2023
Regulus Therapeutics Inc today announced an update on its preclinical studies evaluating a library of oligonucleotides designed to inhibit miR-155 for the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease).
-
Regulus Therapeutics Strengthens Research & Development Leadership
6/12/2023
Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.
-
Regulus Therapeutics Advances to Cohort 2 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
5/16/2023
Regulus Therapeutics Inc. today announced, after review of all available safety data, that it will advance to the second cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD.